nach oben

Wiener Medizinische Wochenschrift

Erschienen in:

19.09.2018 | original article

Neurological complications of systemic tumor therapy

verfasst von: Prof. Dr. Wolfgang Grisold, Wolfgang Löscher, Anna Grisold

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 1-2/2019

Einloggen, um Zugang zu erhalten

Summary

The treatment of malignant tumors has considerably improved in recent years, and also the number of “long term cancer survivors” is increasing.

The spectrum of anti-tumoral agents is increasing at a fast pace and in addition to conventional therapies such as surgery, radiotherapy, and chemotherapy, new drugs with entirely new mechanisms are appearing. Side effects of old and new drugs can affect the central and peripheral nervous system, the neuromuscular junction, and muscle. These side effects often have to be distinguished from other causes and need neurological expertise. Although the majority of patients still receive conventional therapies, several new strategies such as immune therapies are being implemented. These drugs have also drug specific side effects, which do not always follow the classical principles of “toxicity.”

This review focuses on the well-known and described side effects of conventional cancer therapies and adds new observations on new drugs.

Zukas AM, Schiff D. Neurological complications of new chemotherapy agents. Neuro-oncology. 2018;20(1):24–36.PubMed

Greene-Schloesser D, et al. Radiation-induced brain injury: a review. Front Oncol. 2012;2:73.PubMedPubMedCentral

Sharma S, et al. Effect of prophylactic cranial irradiation on overall survival in metastatic small-cell lung cancer: a propensity score-matched analysis. Clin Lung Cancer. 2017; https://doi.org/10.1016/j.cllc.2017.12.003.CrossRefPubMedPubMedCentral

Radcliffe J, et al. Cognitive deficits in long-term survivors of childhood medulloblastoma and other noncortical tumors: age-dependent effects of whole brain radiation. Int J Dev Neurosci. 1994;12(4):327–34.PubMed

Zhao R, et al. Hippocampal-sparing whole-brain radiotherapy for lung cancer. Clin Lung Cancer. 2017;18(2):127–31.PubMed

Mehanna R, Jimenez-Shahed J, Itin I. Three cases of Levodopa-resistant Parkinsonism after radiation therapy. Am J Case Rep. 2016;17:916–20.PubMedPubMedCentral

Pompe RS, von Bueren SO, Mynarek M, von Hoff K, Friedrich C, Kwiecien R, Treulieb W, Lindow C, Deinlein F, Fleischhack G, Kuehl J, Rutkowski S. Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: feasibility, acute toxicity and evidence for efficacy. Eur J Cancer. 2015;51(17):2634–42. https://doi.org/10.1016/j.ejca .2015.08.009.PubMed

Song YP, Colaco RJ. Radiation necrosis—a growing problem in a case of brain metastases following whole brain radiotherapy and stereotactic radiosurgery. Cureus. 2018;10(1):e2037.PubMedPubMedCentral

Shah AH, et al. Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality? J Neurooncol. 2013;112(2):141–52.PubMed

10.

Gujral DM, et al. Radiation-induced carotid artery atherosclerosis. Radiother Oncol. 2014;110(1):31–8.PubMed

11.

Bond KM, et al. Endovascular treatment of carotid blowout syndrome. J Vasc Surg. 2017;65(3):883–8.PubMed

12.

Tully CM, et al. The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents. Cancer. 2016;122(5):712–21.PubMed

13.

Grisold W, Oberndorfer S, Struhal W. Stroke and cancer: a review. Acta Neurol Scand. 2009;119(1):1–16.PubMed

14.

Sweiss KI, Beri R, Shord SS. Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature. Drug Saf. 2008;31(11):989–96.PubMed

15.

Valentine AD, et al. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol. 1998;25(1 Suppl 1):39–47.PubMed

16.

Newton HB. Neurological complications of chemotherapy to the central nervous system. In: Grisold W, Soffietti R, editors. Handbook of clinical neurology 3rd series. Vol. 105. 2012. pp. 903–16.

17.

Simóa M, Rifà-Rosa X, Rodriguez-Fornellsa A, Brunab J, More S. Chemobrain: a systematic review of structural and functional neuroimaging studies. Neurosci Biobehav Rev. 2013;37(8):1311–21.

18.

Gaman AM, et al. The role of oxidative stress in etiopathogenesis of chemotherapy induced cognitive impairment (CICI)-“Chemobrain”. Aging Dis. 2016;7(3):307–17.PubMedPubMedCentral

19.

Simo M, et al. Performance monitoring in lung cancer patients pre- and post-chemotherapy using fine-grained electrophysiological measures. Neuroimage Clin. 2018;18:86–96.PubMed

20.

Ren X, St. Clair DK, Butterfield DA. Dysregulation of cytokine mediated chemotherapy induced cognitive impairment. Pharmacol Res. 2017;117:267–73.PubMed

21.

Kamiya-Matsuoka C, et al. Primary brain tumors and posterior reversible encephalopathy syndrome. Neurooncol Pract. 2014;1(4):184–90.PubMedPubMedCentral

22.

Mescher C, Slungaard A. Posterior reversible encephalopathy syndrome in a postpartum woman with acute lymphoblastic leukaemia after intrathecal methotrexate. BMJ Case Rep. 2017; https://doi.org/10.1136/bcr-2017-220429.CrossRefPubMedPubMedCentral

23.

Deguchi S, et al. Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature. Invest New Drugs. 2018;36(2):346–9.PubMed

24.

Gheith O, et al. Sirolimus-induced combined posterior reversible encephalopathy syndrome and lymphocytic pneumonitis in a renal transplant recipient: case report and review of the literature. Exp Clin Transplant. 2017;15(Suppl 1):170–4.PubMed

25.

Bohra C, Sokol L, Dalia S. Progressive multifocal leukoencephalopathy and monoclonal antibodies: a review. Cancer Control. 2017;24(4):1073274817729901.PubMedPubMedCentral

26.

Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60.PubMed

27.

Kuru S, Khan N, Shaaban H. Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanoma. Int J Crit Illn Inj Sci. 2017;7(3):177–80.PubMedPubMedCentral

28.

McGinnis GJ, Raber J. CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy. Immunotherapy. 2017;9(11):929–41.PubMedPubMedCentral

29.

Pak D, et al. Lhermitte sign after chemo-IMRT of head-and-neck cancer: incidence, doses, and potential mechanisms. Int J Radiat Oncol Biol Phys. 2012;83(5):1528–33.PubMedPubMedCentral

30.

Leung WM, Tsang N‑M, Chang FT, et al. Lhermitte’s sign among nasopharyngeal cancer patients after radiotherapy. Head Neck. 2005;27:187–94.PubMed

31.

O’Reilly A, et al. Lhermitte’s phenomenon and platinum, beware of latency. Oncol Res Treat. 2014;37(10):591–4.PubMed

32.

Pompili A, et al. Symptomatic spinal cord necrosis after irradiation for vertebral metastatic breast cancer. J Clin Oncol. 2011;29(3):e53–e6.PubMed

33.

Bowen J, et al. The post-irradiation lower motor neuron syndrome neuronopathy or radiculopathy? Brain. 1996;119(5):1429–39.PubMed

34.

Cachia D, et al. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neurooncol. 2015;122(2):391–8.PubMedPubMedCentral

35.

Resnick IB, et al. Spinal epidural lipomatosis following haploidentical allogeneic bone marrow transplantation for non-Hodgkin lymphoma. Clin Transplant. 2004;18(6):762–5.PubMed

36.

Grisold W, Grisold A, Löscher WN. Neuromuscular complications in cancer. J Neurol Sci. 2016;367:184–202.PubMed

37.

Grisold W, Grisold A, Löscher W. Cancer therapy and neuromuscular complications: a mini review. Neurology (ECronicon). 2017;9(1):20–6.

38.

Vecht CJ. Arm pain in the patient with breast cancer. J Pain Symptom Manage. 1990;5(2):109–17.PubMed

39.

Orsolya H‑B, Coros MF, Stolnicu S, Naznean A, Georgescu R. Does the surgical management of the intercostobrachial nerve influence the postoperatory paresthesia of the upper limb and life quality in breast cancer patients? Chirurgia (Bucur). 2017;112(4):436–42.

40.

Kääriäinen M, Giordano S, Kauhanen S, Helminen M, Kuokkanen H. No need to cut the nerve in LD reconstruction to avoid jumping of the breast: a prospective randomized study. J Plast Reconstr Aesthet Surg. 2014;67(8):1106–10.PubMed

41.

Gunterberg B, et al. Anorectal function after major resections of the sacrum with bilateral or unilateral sacrifice of sacral nerves. Br J Surg. 1976;63(7):546–54.PubMed

42.

Brooks AD, et al. Resection of the sciatic, peroneal, or tibial nerves: assessment of functional status. Ann Surg Oncol. 2002;9(1):41–7.PubMed

43.

Stubblefield MD. Clinical evaluation and management of radiation fibrosis syndrome. Phys Med Rehabil Clin N Am. 2017;28(1):89–100.PubMed

44.

Sood SS, et al. Brachial plexopathy after stereotactic body radiation therapy for apical lung cancer: dosimetric analysis and preliminary clinical outcomes. Adv Radiat Oncol. 2018;3(1):81–6.PubMed

45.

Kounis NG, Macauley MB, Ghorbal MS. Iliacus hematoma syndrome. Can Med Assoc J. 1975;112(7):872–3.PubMedPubMedCentral

46.

Brejt N, et al. Pelvic radiculopathies, lumbosacral plexopathies, and neuropathies in oncologic disease: a multidisciplinary approach to a diagnostic challenge. Cancer Imaging. 2013;13(4):591–601.PubMedPubMedCentral

47.

Capek S, et al. Perineural spread of pelvic malignancies to the lumbosacral plexus and beyond: clinical and imaging patterns. Neurosurg Focus. 2015;39(3):E14.PubMed

48.

Dalmau J, Graus F, Marco M. ‘Hot and dry foot’ as initial manifestation of neoplastic lumbosacral plexopathy. Neurology. 1989;39(6):871–2.PubMed

49.

Evans RJ, Watson CP. The hot foot syndrome: evans’ sign and the old way. Pain Res Manag. 2012;17(1):31–4.PubMedPubMedCentral

50.

Gikas PD, et al. Post-radiation sciatic neuropathy: a case report and review of the literature. World J Surg Oncol. 2008;6:130.PubMedPubMedCentral

51.

Jones L, Bradley L. Late and multifocal presentations of malignant peripheral nerve sheath tumours following radiotherapy. BMJ Case Rep. 2015; https://doi.org/10.1136/bcr-2014-207681.CrossRefPubMedPubMedCentral

52.

Staff NP, et al. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6):772–81.PubMedPubMedCentral

53.

Ibanez-Julia MJ, et al. Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability. Acta Oncol. 2018;57(3):403–11.PubMed

54.

Kerckhove N, et al. Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. Front Pharmacol. 2017;8:86.PubMedPubMedCentral

55.

Gu Y, et al. Immune mediated neuropathy following checkpoint immunotherapy. J Clin Neurosci. 2017;45:14–7.PubMed

56.

Kolb NA, et al. The neuromuscular complications of immune checkpoint inhibitor therapy. Muscle Nerve. 2018; https://doi.org/10.1002/mus.26070.CrossRefPubMedPubMedCentral

57.

Tanaka R, Maruyama H, Tomidokoro Y, Yanagiha K, Hirabayashi T, Ishii A, Okune M, Inoue S, Sekine I, Tamaoka A, Fujimoto M. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report. Jpn J Clin Oncol. 2016;46(9):875–8. https://doi.org/10.1093/jjco/hyw090.CrossRefPubMed

58.

Kao JC, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol. 2017;74(10):1216–22.PubMedPubMedCentral

59.

Binda D, et al. Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). Eur J Cancer. 2013;49(13):2910–8.PubMed

60.

Cornblath DR, et al. Total neuropathy score: validation and reliability study. Neurology. 1999;53(8):1660–4.PubMed

61.

Shah A, et al. Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. J Neurol Neurosurg Psychiatr. 2018; https://doi.org/10.1136/jnnp-2017-317215.CrossRef

62.

Nayar G, et al. Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget. 2017;8(42):73312–28.PubMedPubMedCentral

63.

Sun V, et al. Toxicities, complications, and clinical encounters during intraperitoneal chemotherapy in 17 women with ovarian cancer. Eur J Oncol Nurs. 2013;17(3):375–80.PubMed

64.

Busse O, Aigner K, Wilimzig H. Peripheral nerve damage following isolated extremity perfusion with cis-platinum. Recent Results Cancer Res. 1983;86:264–7.PubMed

65.

Ari P, et al. Treatment of transient peripheral neuropathy during chimeric 14.18 antibody therapy in children with neuroblastoma: a case series. J Pediatr Hematol Oncol. 2018;40(2):e113–e6.PubMed

66.

Shaw AT, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18(12):1590–9.PubMedPubMedCentral

67.

Kanaan Z, et al. Guillain-Barre syndrome following treatment with Sunitinib Malate. Case Rep Oncol Med. 2014;2014:712040.PubMedPubMedCentral

68.

Krop I, Winer EP. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Clin Cancer Res. 2014;20(1):15–20.PubMed

69.

Mariotto S, Ferrari S, Monaco S. Brentuximab vedotin-induced peripheral neuropathy: looking at microtubules. J Neurooncol. 2018; https://doi.org/10.1007/s11060-018-2743-6.CrossRefPubMed

70.

Yamanouchi K, et al. The relationship between peripheral neuropathy induced by Docetaxel and systemic inflammation-based parameters in patients with breast cancer. Anticancer Res. 2017;37(12):6947–51.PubMed

71.

Lees JG, et al. Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. Eur J Cancer. 2017;73:22–9.PubMed

72.

Batchelor TT, et al. Steroid myopathy in cancer patients. Neurology. 1997;48(5):1234–8.PubMed

73.

Basualto-Alarcon C, et al. Sarcopenia and androgens: a link between pathology and treatment. Front Endocrinol (Lausanne). 2014;5:217.

74.

Mieog JS, et al. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2–3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet Oncol. 2012;13(4):420–32.PubMed

75.

Hoffmann S, et al. Glucocorticoids in myasthenia gravis—if, when, how, and how much? Acta Neurol Scand. 2014;130(4):211–21.PubMed

76.

Bhattacharyya S, Darby R, Berkowitz AL. Antibiotic-induced neurotoxicity. Curr Infect Dis Rep. 2014;16(12):448.PubMed

77.

Loochtan AI, Nickolich MS, Hobson-Webb LD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve. 2015; https://doi.org/10.1002/mus.24648.CrossRefPubMed

78.

Suzuki S. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017;89:1127–34.PubMed

79.

Chen JH, et al. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review. Medicine (Baltimore). 2017;96(50):e9262.

80.

Fearon K, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95.PubMed

81.

Baracos VE, et al. Cancer-associated cachexia. Nat Rev Dis Primers. 2018;4:17105.PubMed

82.

Aussy A, Boyer O, Cordel N. Dermatomyositis and immune-mediated necrotizing myopathies: a window on autoimmunity and cancer. Front Immunol. 2017;8:992.PubMedPubMedCentral

83.

Argiles JM, et al. Novel targeted therapies for cancer cachexia. Biochem J. 2017;474(16):2663–78.PubMed

84.

Perel-Winkler A, et al. A case of Docetaxel induced myositis and review of the literature. Case Rep Rheumatol. 2015;2015:795242.PubMedPubMedCentral

85.

Spielmann L, et al. Gemcitabine-induced myopathy. Semin Arthritis Rheum. 2014;43(6):784–91.PubMed

86.

Minami H, et al. Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors. Cancer Sci. 2016;107(10):1477–83.PubMedPubMedCentral

87.

Yoshidome Y, et al. A case of polymyositis complicated with myasthenic crisis. Clin Rheumatol. 2007;26(9):1569–70.PubMed

88.

Muto Y, et al. Success of rechallenging dabrafenib and trametinib combination therapy after trametinib-induced rhabdomyolysis: a case report. Melanoma Res. 2018;28(2):151–4.PubMed

89.

Burris HA 3rd, Hurtig J. Radiation recall with anticancer agents. Oncologist. 2010;15(11):1227–37.PubMedPubMedCentral

90.

Stephenson AL, Mackenzie IRA, Levy RD, Road J. Myositis associated graft-versus-host-disease presenting as respiratory muscle weakness. Thorax. 2001;56:82–4.PubMedPubMedCentral

91.

Smith CI, et al. Myasthenia gravis after bone-marrow transplantation. Evidence for a donor origin. N Engl J Med. 1983;309(25):1565–8.PubMed

92.

Leeper HE, Acquaye AA, Bell S, Clarke JL, Forst D, Laack NN, Link MJ, Taylor JW, Armstrong TS. Survivorship care planning in neuro-oncology. Neurooncol Pract. 2017; https://doi.org/10.1093/nop/npx034.CrossRef

Titel: Neurological complications of systemic tumor therapy
verfasst von: Prof. Dr. Wolfgang Grisold
Wolfgang Löscher
Anna Grisold
Publikationsdatum: 19.09.2018
Verlag: Springer Vienna
Erschienen in: Wiener Medizinische Wochenschrift / Ausgabe 1-2/2019
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI: https://doi.org/10.1007/s10354-018-0654-y

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1-2/2019

68Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?

Current status of functional imaging in neuroblastoma, pheochromocytoma, and paraganglioma disease

Nuklearmedizin – Rising or falling star?

PET-CT bei Prostatakarzinom gezielt anwenden

Acute edema induced by toluidine blue extravasation—first report

Darstellung und Lokalisation von Nebenschilddrüsenadenomen mit F‑18 Cholin PET/CT